EL vs LRLCY: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
LRLCY is the larger of the two ($241.97B market cap): the incumbent the market prices for continued execution (25.98x forward earnings, beta 0.86). EL is the smaller challenger ($37.88B), priced similarly on forward earnings (26.60x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
EL vs LRLCY: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | EL | LRLCY | What it tells you |
|---|---|---|---|
| Market cap | $37.88B | $241.97B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 26.60 | 25.98 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 209.08 | 33.05 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.26 | 0.86 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 69% of range | 73% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 9.94 | 6.36 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how EL and LRLCY affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. EL and LRLCY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined EL and LRLCY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does The Estée Lauder Companies (EL) do?
Estee Lauder sells prestige beauty across four categories: skin care (~$5.5 billion of net sales in the first nine months of fiscal 2026), makeup (~$3.3 billion), fragrance (~$2.2 billion) and hair care (~$0.4 billion). The portfolio spans roughly two dozen brands, including the namesake Estee Lauder line, La Mer, Clinique, M.A.C, Bobbi Brown, Too Faced, Smashbox, Dr.Jart+, Aveda, Origins, Le Labo, Jo Malone London, Tom Ford Beauty, Frederic Malle and The Ordinary. Distribution runs through department stores, perfumeries, specialty multi-brand retailers, freestanding stores, e-commerce, third-party marketplaces and travel retail, with the travel retail business reported inside the Asia/Pacific region. Geographically the company is split between the Americas (~$3.5 billion in the nine months), Europe, the UK, Ireland and emerging markets (~$2.9 billion), Asia/Pacific (~$2.8 billion) and Mainland China (~$2.2 billion), which makes China and Asian travel retail unusually important to results.
What does L'Oréal S.A. (LRLCY) do?
L'Oréal S.A. is a Paris-based beauty group with more than 35 international brands sold in about 150 countries. It makes money by selling skincare, makeup, hair care and fragrance through four divisions: Consumer Products (L'Oréal Paris, Maybelline, Garnier), the largest by sales; L'Oréal Luxe (Lancôme, Yves Saint Laurent Beauté, Armani, Prada, Valentino, Aesop and, since April 2026, Creed); Dermatological Beauty (La Roche-Posay, CeraVe, Vichy, SkinCeuticals); and Professional Products (Kérastase, Redken), sold through salons. The Bettencourt Meyers family owns roughly a third of the company and Nestlé about a fifth. LRLCY is an unsponsored ADR that trades in dollars and tracks the Euronext Paris share (ticker OR) adjusted for the euro-dollar rate.
EL vs LRLCY: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- EL drivers: Margin recovery from the Profit Recovery and Growth Plan; China and Asian travel retail stabilising.
- LRLCY drivers: Dermatological Beauty; Luxury fragrance and Kering Beauté.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Reported earnings are barely positive: fiscal 2026 GAAP net income was ~$182 million, or ~$0.50 a share, and the June quarter alone lost ~$116 million, so at ~213 times trailing GAAP earnings the valuation rests on adjusted and forward numbers rather than delivered GAAP profit. For LRLCY, valuation is the main risk.
EL or LRLCY: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick EL if you believe its drivers more; LRLCY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the EL and LRLCY guides.
EL vs LRLCY: the full fundamentals
EL. At ~$107, EL trades near ~32 times fiscal 2027 consensus adjusted EPS of ~$3.32 and ~27 times the fiscal 2028 estimate of ~$3.93; the trailing GAAP multiple above 200x is not meaningful because restructuring and settlement charges sit between gross and net profit. The gap between a ~75.5% gross margin and a ~7.0% operating margin is where the whole debate sits, and the multiple reflects an assumption that most of those charges do not repeat. Free cash flow of ~$1.81 billion over the trailing year is the strongest sign the repair is real.
LRLCY. L'Oréal has long traded at a premium to consumer-staples peers because of its steady growth and expanding margins. First-half 2026 net profit excluding one-off items was ~€3.96 billion, up 4.7%, and reported attributable net profit was ~€3.55 billion. LRLCY traded between about $78.82 and $95.48 over the past year. Analysts expect 2026 revenue of roughly €47.0 billion, up about 6.8%, and around €50.0 billion in 2027. The third-quarter sales release on October 22, 2026 (after the Paris close) is the next test of whether the faster first-half pace carried into the second half.
Headline figures (approximate, October 2026): EL shows revenue (fy2026, ended june 30) ~$15.05 billion, up ~5%, net income (fy2026) ~$182 million GAAP, EPS ~$0.50; adjusted EPS ~$2.51, gross / operating margin (ttm) ~75.5% gross, ~7.0% operating, market capitalisation ~$38.7 billion at ~$107 per share; LRLCY shows revenue (ttm) ~€45.4 billion (~$53 billion), h1 2026 sales growth (like-for-like) ~6.8% (Q2 alone ~6.0%), operating margin (h1 2026) ~21.3%, a first-half record, market cap ~$242 billion.
The bottom line: EL vs LRLCY
EL and LRLCY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined EL and LRLCY exposure against your real portfolio. It is not an investment adviser.
Wondering how EL or LRLCY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in The Estée Lauder Companies with AI
Connect the broker you already use and ask Walnut's AI how EL fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between EL and LRLCY?
+
Estee Lauder sells prestige beauty across four categories: skin care (~$5.5 billion of net sales in the first nine months of fiscal 2026), makeup (~$3.3 billion), fragrance (~$2.2 billion) and hair care (~$0.4 billion). L'Oréal S.A. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is EL or LRLCY the better stock?
+
Neither is universally better. LRLCY is the larger incumbent; EL is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, EL or LRLCY?
+
On forward P/E (as of October 2026), EL trades at 26.60x and LRLCY at 25.98x, so LRLCY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both EL and LRLCY?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of EL vs LRLCY?
+
EL: Reported earnings are barely positive: fiscal 2026 GAAP net income was ~$182 million, or ~$0.50 a share, and the June quarter alone lost ~$116 million, so at ~213 times trailing GAAP earnings the valuation rests on adjusted and forward numbers rather than delivered GAAP profit. Leverage is meaningful at ~$9.25 billion of total debt against ~$3.5 billion of cash, roughly ~$5.75 billion net, while the Class A buyback has been suspended since December 2022 and the dividend was cut to $0.35 per quarter. A securities class action in the Southern District of New York (In re The Estee Lauder Companies, Inc. Securities Litigation, No. 1:23-cv-10669, S.D.N.Y.) over travel retail and daigou disclosures survived a motion to dismiss in March 2025 and reached an agreement in principle to settle for $210 million on April 2, 2026, with preliminary approval granted May 13, 2026 and a final approval hearing scheduled for August 20, 2026; several shareholder derivative suits over the same conduct remain outstanding in New York and Delaware, and cosmetic talcum powder asbestos claims are being resolved under settlement frameworks running through 2029. Tariffs are expected to reduce fiscal 2026 profitability by ~$100 million, and because tariff costs are capitalised in inventory for roughly six months, later rate reductions do not help the current year. Middle East disruption, which touched ~2% of fiscal 2025 net sales, was flagged as a larger drag on the June 2026 quarter than on the March quarter. After a ~30% three-month rally the stock has also priced in a good part of the recovery, which raises the bar for the November 2, 2026 report. LRLCY: Valuation is the main risk. At roughly 33 times trailing earnings, a modest growth miss can move the shares sharply, as happened in October 2025 when third-quarter like-for-like growth of 4.2% came in below expectations. Consensus now looks for third-quarter 2026 revenue of about €11.2 billion, up roughly 8.6% on a reported basis, so the bar for the October 22 release is high. Consumer Products, the largest division, grew only 4.1% in the first half, and mass beauty in the US and Europe faces competition from cheaper indie and private-label brands. China's recovery has been uneven, and travel retail remains volatile. Kering Beauté adds integration risk and ties part of Luxe to the health of fashion houses whose brands L'Oréal licenses rather than owns. Professional Products' double-digit growth partly reflects pricing, which may not repeat. For US holders, a stronger dollar reduces returns, the OTC ADR can trade thinly with wider spreads, and French withholding tax applies to dividends.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell EL or LRLCY; figures are approximate and dated (as of October 2026). Verify current data before investing.